摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-Ethoxycarbonylamino-1-ethyl-3,4-dihydroisoquinoline | 347146-52-5

中文名称
——
中文别名
——
英文名称
6-Ethoxycarbonylamino-1-ethyl-3,4-dihydroisoquinoline
英文别名
ethyl N-(1-ethyl-3,4-dihydroisoquinolin-6-yl)carbamate
6-Ethoxycarbonylamino-1-ethyl-3,4-dihydroisoquinoline化学式
CAS
347146-52-5
化学式
C14H18N2O2
mdl
——
分子量
246.309
InChiKey
CHDTZVSQNQAQAC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    50.7
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • Integrin expression inhibitors
    申请人:——
    公开号:US20040018192A1
    公开(公告)日:2004-01-29
    The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. 1 In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR 4b R 5b ) m b — (wherein R 4b and R 5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and m b means an integer of 1 or 2); R 1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.
    本发明提供了一种整合素表达抑制剂,以及基于整合素抑制作用的用于治疗动脉硬化、屑病、癌症、视网膜血管生成、糖尿病视网膜病变或炎症性疾病的药剂、抗凝剂或癌症转移抑制剂。即提供了一种包含以下式(I)所表示的磺胺化合物、其药理学上可接受的盐或其合物作为活性成分的整合素表达抑制剂。 在该式中,B表示一个C6-C10芳基环或6-至10成员杂芳基环,可能具有取代基,并且环的一部分可能是饱和的;K表示一个单键,-CH═CH-或-(CR 4b R 5b ) m b -(其中R 4b 和R 5b 相同或不同,各自表示氢原子或C1-C4烷基;m b 表示1或2的整数);R 1 表示氢原子或C1-C6烷基;Z表示一个单键或-CO-NH-;R表示一个C6-C10芳基环或6-至10成员杂芳基环,可能具有取代基,并且环的一部分可能是饱和的,分别。
  • Sulfonamide-containing heterocyclic compounds
    申请人:——
    公开号:US20030144507A1
    公开(公告)日:2003-07-31
    The present invention provides a sulfonamide- or sulfonylurea-containing heterocyclic compounds. Specifically, it provides a heterocyclic compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. 1 In the formula, A is hydrogen atom, a halogen atom, a C1-C4 alkyl or alkoxy group which may be substituted with a halogen atom, or cyano group; B is an optionally substituted aryl group or monocyclic heteroaryl group, or: 2 (wherein, the ring Q is an aromatic ring which may have nitrogen atom; and the ring M is a ring sharing a double bond with the ring Q, which ring may have a heteroatom; and the rings Q and M may share nitrogen atom); K is a single bond; T, W, X and Y are the same as or different from each other and each is ═C(D)— (wherein, D is hydrogen or a halogen atom) or nitrogen atom; U and V are the same as or different from each other and each is ═C(D)—, nitrogen atom, —CH 2 —, oxygen atom or —CO—; Z is a single bond or —CO—NH—; and R 1 is hydrogen atom, etc.
    本发明提供了含有磺胺基或磺酰基杂环化合物。具体而言,提供了由式(I)表示的杂环化合物,其药学上可接受的盐或其合物。 在该式中,A为氢原子、卤原子、可能被卤原子取代的C1-C4烷基或烷氧基,或基;B为可选择取代的芳基或单环杂芳基,或: (其中,环Q为可能含有氮原子的芳环;环M为与环Q共享双键的环,该环可能含有杂原子;环Q和环M可能共享氮原子);K为单键;T、W、X和Y彼此相同或不同,每个都是═C(D)—(其中,D为氢或卤原子)或氮原子;U和V彼此相同或不同,每个都是═C(D)—、氮原子、—CH 2 —、氧原子或—CO—;Z为单键或—CO—NH—;R 1 为氢原子,等等。
  • Integrin expression inhibitor
    申请人:Wakabayashi Toshiaki
    公开号:US20050176712A1
    公开(公告)日:2005-08-11
    The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them, wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR 4b R 5b ) m b — (wherein R 4b and R 5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and m b means an integer of 1 or 2); R 1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.
    本发明提供了一种整合素表达抑制剂,并提供了一种基于整合素抑制作用的用于治疗动脉硬化、屑病、癌症、视网膜血管生成、糖尿病视网膜病变或炎症性疾病的药剂、抗凝剂或癌症转移抑制剂。换句话说,本发明提供了一种整合素表达抑制剂,其包括以下式(I)所表示的磺酰胺化合物作为活性成分、其药学上可接受的盐或其合物: 其中,在上述式中,B表示C6-C10芳基环或6-至10元杂环芳基环,其中可能有取代基,并且环的一部分可能是饱和的;K表示单键,-CH═CH-或-(CR4bR5b)mb-(其中R4b和R5b相同或不同,每个表示氢原子或C1-C4烷基;mb表示1或2的整数);R1表示氢原子或C1-C6烷基;Z表示单键或-CO-NH-;R分别表示C6-C10芳基环或6-至10元杂环芳基环,其中可能有取代基,并且环的一部分可能是饱和的。
  • INTEGRIN EXPRESSION INHIBITOR
    申请人:WAKABAYASHI Toshiaki
    公开号:US20100267754A1
    公开(公告)日:2010-10-21
    The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them, wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR 4b R 5b ) m b — (wherein R 4b and R 5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and m b means an integer of 1 or 2); R 1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.
    本发明提供了一种整合素表达抑制剂,以及一种用于治疗动脉硬化、屑病、癌症、视网膜血管生成、糖尿病视网膜病变或炎症性疾病、抗凝剂或癌症转移抑制剂的药剂,其基于整合素抑制作用。即,提供一种整合素表达抑制剂,其包括以下式(I)所表示的磺酰胺化合物作为活性成分,其药理学上可接受的盐或合物,其中在该式中,B表示一个C6-C10芳基环或6-到10成员杂环环,可以有取代基,在环中的一部分可能是饱和的;K表示单键,—CH═CH—或—(CR4bR5b)mb—(其中R4b和R5b相同或不同,每个表示氢原子或C1-C4烷基;mb表示1或2的整数);R1表示氢原子或C1-C6烷基;Z表示单键或—CO—NH—;R分别表示C6-C10芳基环或6-到10成员杂环环,可以有取代基,在环中的一部分可能是饱和的。
  • INTEGRIN EXPRESSION INHIBITORS
    申请人:Eisai Co., Ltd.
    公开号:EP1258252A1
    公开(公告)日:2002-11-20
    The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, -CH=CH- or - (CR4bR5b)mb- (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or -CO-NH-; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.
    本发明提供了一种整合素表达抑制剂,以及一种基于整合素抑制作用的用于治疗动脉硬化、屑病、癌症、视网膜血管生成、糖尿病视网膜病变或炎症性疾病的制剂、抗凝剂或癌症转移抑制剂。也就是说,它提供了一种整合素表达抑制剂,其活性成分包括下式(I)代表的磺酰胺化合物、其药理学上可接受的盐或它们的合物。 式中,B 指 C6-C10 芳基环或 6 至 10 元杂芳基环,可具有取代基,其中环的一部分可为饱和;K 指单键、-CH=CH- 或-(CR4bR5b)mb-(其中 R4b 和 R5b 彼此相同或不同,各自指氢原子或 C1-C4 烷基;R1指氢原子或C1-C6烷基;Z指单键或-CO-NH-;R指C6-C10芳基环或6-至10元杂芳基环,可分别具有一个取代基,其中环的一部分可为饱和。
查看更多

同类化合物

法莫汀 诺斯卡品杂质2 美莫汀盐酸盐 美莫汀 法莫汀盐酸盐 氯化可替宁 异喹啉,3,4-二氢-6,7-二甲氧基-3,3-二甲基- 异喹啉,3,4-二氢-6,7-二甲氧基-1-苯基-,盐酸 异喹啉,3,4-二氢-5,6,7-三甲氧基-1-甲基- 丁-2-烯二酸;7-甲基-3-[(4-甲基哌嗪-1-基)甲基]-1-苯基-3,4-二氢异喹啉 7-苄氧基-6-甲氧基-3,4-二氢异吲哚 7-羟基-6-甲氧基-3,4-二氢异喹啉 7-硝基-3,4-二氢异喹啉 7-甲基-3,4-二氢异喹啉 7-溴二氢异喹啉 7-溴-3,4-二氢异喹啉盐酸盐 7-溴-1-异丙基-3,4-二氢异喹啉 7-氯-1-苯基-3,4-二氢异喹啉 7-氟-3,4-二氢异喹啉 7-氟-1-甲基-3,4-二氢异喹啉 7,8-二甲氧基-3,4-二氢异喹啉 7,8-二氢-[1,3]二氧代[4,5-g]异喹啉 7,8-二氢-5-[4-(异丙基磺酰基)苯基]-1,3-二氧杂环戊并[4,5-g]异喹啉 6-苄氧基-7-甲氧基-3,4-二氢-异喹啉 6-羟基-7-甲氧基-2-甲基-3,4-二氢异喹啉正离子 6-甲氧基-3,4-二氢-异喹啉 6-甲氧基-2-苯基-1-(3-(三氟甲基)苯基)-3,4-二氢异喹啉-2-碘化物 6-甲氧基-1-甲基-3,4-二氢异喹啉 6-氯-1-(2-氯-苯基)-7-甲氧基-3,4-二氢-异喹啉 6-氯-1-(2-异丙基-苯基)-7-甲氧基-3,4-二氢-异喹啉 6-氯-1-(2,6-二甲基-苯基)-7-甲氧基-3,4-二氢-异喹啉 6-氟-3,4-二氢异喹啉 6,7-二甲氧基-3-甲基-3,4-二氢异喹啉盐酸盐 6,7-二甲氧基-3,4-二氢异喹啉盐酸盐 6,7-二甲氧基-3,4-二氢异喹啉 6,7-二甲氧基-1-(4-甲氧基苯基)-3,4-二氢异喹啉 6,7-二甲氧基-1-(3,4-二甲氧基苯基)-3-羟基甲基-3,4-二氢异喹啉 6,7-二甲氧基-1,3,3-三甲基-3,4-二氢异喹啉氢碘化 6,7-二甲-1,3-二甲基-3,4-二氢异喹啉盐酸盐 6,7-二乙氧基-3,4-二氢异喹啉盐酸盐 5-甲氧基-1-甲基-3,4-二氢异喹啉 5-甲基吡咯-3-腈 5-甲基-7,8-二氢-[1,3]二氧戊环并[4,5-G]异喹啉 5-甲基-3,4-二氢-异喹啉 5-氯-2-(6,7-二甲氧基-3,4-二氢异喹啉-1-基)苯胺 5,8-二甲氧基-3-甲基-3,4-二氢-异喹啉 4-甲氧基-7,8-二氢[1,3]二氧杂环戊并[4,5-g]异喹啉 4-甲氧基-6-甲基-7,8-二氢[1,3]二氧杂环戊并[4,5-g]异喹啉-6-鎓碘化物 4-氯-2-(6,7-二甲氧基-3,4-二氢异喹啉-1-基)苯胺 4-(6,7-二甲氧基-3,4-二氢异喹啉-1-基)庚二腈